Introduction to a Crucial Pharmaceutical Intermediate

In the ever-evolving world of pharmaceuticals, intermediates play an indispensable role in the synthesis of life-saving drugs. One such compound, 4-(4-bromo-2-fluoroanilino)-6-methoxy-1H-quinazolin-7-one, identified by its CAS number 196603-96-0, stands out as a key building block in the production of Vandetanib, a targeted therapy drug. This white powder, with a molecular formula of C15H11BrFN3O2 and a molecular weight of 364.16900, embodies the precision and complexity of modern medicinal chemistry. Its unique chemical structure and properties make it an essential component for researchers and manufacturers aiming to develop advanced therapeutic solutions.

Chemical and Physical Properties Unveiled

Understanding the characteristics of 4-(4-bromo-2-fluoroanilino)-6-methoxy-1H-quinazolin-7-one is vital for its effective application. This compound boasts a density of 1.664 g/cm³, indicating its compact molecular arrangement. With a melting point ranging from 262 to 264ºC, it demonstrates thermal stability, a critical factor during synthesis processes that involve elevated temperatures. Its boiling point, calculated at 470.985ºC, and flash point of 238.643ºC further underscore its robustness under various conditions. These attributes ensure that the compound remains intact during the rigorous steps of pharmaceutical production, making it a reliable choice for manufacturers seeking consistency and quality.

The purity of this intermediate, specified at ≥98.0%, is another testament to its high standards. Typically packaged in 25 kg drums—or customized according to client needs—it is designed for practical handling and storage. For optimal preservation, it should be stored in a cool, ventilated environment, safeguarding its integrity for downstream applications.

Role as a Vandetanib Intermediate

The primary application of 4-(4-bromo-2-fluoroanilino)-6-methoxy-1H-quinazolin-7-one lies in its role as an intermediate in the synthesis of Vandetanib, a kinase inhibitor used in cancer treatment. Vandetanib targets vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR), key players in tumor growth and angiogenesis. The presence of bromine and fluorine atoms in the compound’s structure enhances its reactivity and specificity, facilitating the formation of Vandetanib’s complex molecular framework. This makes it a cornerstone for pharmaceutical companies focused on oncology drug development.

Given its significance, the demand for 4-(4-bromo-2-fluoroanilino)-6-methoxy-1H-quinazolin-7-one manufacturer in China has surged, as the region is a hub for chemical production. Suppliers in this market prioritize quality and compliance with international standards, ensuring that the intermediate meets the stringent requirements of drug synthesis.

Manufacturing and Supply Chain Considerations

Producing this compound requires advanced chemical engineering expertise. The process involves precise control over reaction conditions to achieve the desired purity and yield. Manufacturers must navigate challenges such as maintaining the stability of the methoxy and anilino groups while integrating the bromine and fluorine substituents. This complexity underscores the importance of partnering with a reputable 4-(4-bromo-2-fluoroanilino)-6-methoxy-1H-quinazolin-7-one supplier in China, where cutting-edge facilities and skilled professionals ensure top-tier output.

The global supply chain for this intermediate is influenced by patent restrictions, as noted in its documentation: it is not offered in countries where valid patents apply. This legal nuance highlights the need for manufacturers and buyers to stay informed about intellectual property regulations, ensuring ethical and compliant trade practices.

Applications Beyond Vandetanib

While its primary use is tied to Vandetanib, the versatility of 4-(4-bromo-2-fluoroanilino)-6-methoxy-1H-quinazolin-7-one suggests potential in other research areas. Its quinazolinone backbone—a heterocyclic structure known for biological activity—could inspire the development of novel compounds targeting different kinases or cellular pathways. Researchers exploring kinase inhibition or anti-angiogenic therapies may find this intermediate a valuable starting point for innovation. As the pharmaceutical industry continues to push boundaries, the compound’s adaptability positions it as a candidate for future therapeutic breakthroughs.

For those seeking a Vandetanib intermediate supplier in China, this compound’s availability in high purity and customizable packaging makes it an attractive option. Its consistent quality supports both small-scale laboratory experiments and large-scale industrial production.

Storage and Handling Best Practices

To maximize the shelf life and efficacy of 4-(4-bromo-2-fluoroanilino)-6-methoxy-1H-quinazolin-7-one, proper storage is paramount. A cool, well-ventilated space prevents degradation due to heat or humidity, preserving its chemical integrity. Handlers should also adhere to safety protocols, given its role in pharmaceutical synthesis, where contamination or mishandling could compromise downstream results. These practices ensure that the compound remains a dependable resource for manufacturers and researchers alike.

Our Commitment to Excellence

At NINGBO INNO PHARMCHEM CO.,LTD., we pride ourselves on being a leader in the realm of fine chemicals and pharmaceutical intermediates. Our core business encompasses the research, development, and production of high-quality compounds like 4-(4-bromo-2-fluoroanilino)-6-methoxy-1H-quinazolin-7-one. We specialize in continuous flow process development and equipment manufacturing, boasting our own pilot workshop and a robust network of external large-scale production platforms. Our expertise spans a range of reaction types, including high-temperature, high-pressure, nitration, oxidation, and continuous distillation processes.

Our R&D and manufacturing services cover a wide array of products, including bromides, boric acids, thiophenes, indoles, imidazoles, thiazoles, piperazines, pyrazines, and more. We cater to production volumes ranging from 100 kg to 100 metric tons annually, focusing on compounds requiring up to five synthetic steps. Whether you need intermediates for pharmaceuticals or fine chemicals for specialized applications, we are equipped to meet your needs. For any additional requirements or inquiries, please feel free to contact us—we’re here to support your success in chemical innovation.

News you might interested in